Opinion
Video
ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones discusses ESR1 mutation testing with Gradishar, Callahan, and Vidal. Gradishar underscores the necessity of ESR1 testing for prescribing oral selective estrogen receptor degraders (SERDs), emphasizing precision medicine’s role in decision-making for metastatic ER+ cancer.
Callahan prefers panel testing over isolated ESR1 mutation testing, highlighting the acquired nature of ESR1 mutations and the benefits of liquid biopsy for higher yield and convenience. Vidal supports panel testing, combining tissue and liquid biopsies to comprehensively understand tumor heterogeneity.
The discussion provides valuable insights into the evolving landscape of precision medicine and the importance of strategic timing and testing methods in incorporating ESR1 mutation testing into clinical practices.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
